Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Masatoshi Kudo
Topics & Concepts
NivolumabIpilimumabMedicineHepatocellular carcinomaImmunotherapyOncologyInternal medicineFirst lineCancer researchCancerHepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and TreatmentHepatitis B Virus Studies